The mechanism of action of ArtinM in these studies was shown to be dependent of the Toll-like 2 receptor for production of IL-12. More recently, Selleckchem NVP-BKM120 the prophylactic administration of ArtinM in both native and recombinant forms showed protection against P. brasiliensis, with reduction of the fungal load and the incidence of granuloma, associated with increased levels of IL-12, IFN-γ, TNF-α and NO, inducing protective Th1-type immune response [43]. Previous studies showed that the particular delivery vehicle may bias the immune response towards a more active response,

and innate responses are likely important for determining the protective effects in these models, stimulating CDK activation the parasite-specific Th1 immune response

and antibody responses. These data reinforce that protein–carbohydrate binding is important in the immune response against N. caninum. In the present study, the mannose-binding is somehow necessary for this effect, since the mannose-binding lectin ArtinM was a better adjuvant than the galactose-binding lectin Jacalin in immunization against neosporosis. Altogether, it can be concluded that the ArtinM lectin promotes resistance against N. caninum in immunized mice, through the induction of Th1-biased pro-inflammatory immune response, constituting a potential adjuvant candidate for vaccine formulations against neosporosis and should be approached in subsequent investigations in congenital

infection models. In addition, considering that the current vaccination strategies against neosporosis in the field are demonstrating low efficacy, as they result in partial protection, our findings may constitute an inexpensive and viable method for herd vaccination. This work was supported by Brazilian Funding Agencies (CNPq, FAPEMIG and CAPES). M.R.D.C., C.M.M. and F.M.S. are recipients of fellowships from CNPq. N.M. S., T.W.P.M., M.C.R., J.R.M. and see more D.A.O.S are CNPq researchers. “
“Hepatitis B virus (HBV) infection is still a major public health problem in Brazil. It is estimated that at least 15% of the population has been exposed to HBV [1]. Wide territory and cultural and economic differences influence the unequal distribution of hepatitis B throughout the country. Certain areas have a higher HBV prevalence, such as the western Amazon and even some parts of southern Brazil. Hepatitis B vaccination began in 1989 in some regions of Brazil through immunization campaigns. In 1998, the vaccine became available in more regions to children younger than 1 year of age and to high-risk populations. Afterwards, vaccination coverage was extended to health students, members of the military and adolescents up to 15 years of age.